Información del artículo
El Texto completo está disponible en PDF
Biblografía
[1.]
E. Özyilkan, T. Erbas, H. Simsek, F. Telatar, B. Kayhan, H. Telatar.
Increased prevalence of hepatitis C virus antibodies in patients with diabetes mellitus.
J Intern Med, 235 (1994), pp. 283-284
[2.]
R. Simó, C. Hernández, J. Genescà, R. Jardí, J. Mesa.
High prevalence of hepatitis C virus infection in diabetic patients.
Diabetes Care, 19 (1996), pp. 998-1000
[3.]
A.L. Mason, J.Y. Lau, N. Hoang, K. Qian, G.J. Alexander, L. Xu, et al.
Association of diabetes mellitus and chronic hepatitis C virus infection.
Hepatology, 29 (1999), pp. 328-333
[4.]
S.H. Mehta, F.L. Brancati, M.S. Sulkowski, S.A. Strathdee, M. Szklo, D.L. Thomas.
Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States.
Ann Intern Med, 133 (2000), pp. 592-599
[5.]
S.H. Mehta, F.L. Brancati, S.A. Strathdee, J.S. Pankow, D. Netski, J. Coresh, et al.
Hepatitis C virus infection and incident type 2 diabetes.
Hepatology, 38 (2003), pp. 50-56
[6.]
S. Caronia, K. Taylor, L. Pagliaro, C. Carr, U. Palazzo, J. Petrik, et al.
Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection.
Hepatology, 30 (1999), pp. 1059-1063
[7.]
H. Knobler, R. Schihmanter, A. Zifroni, G. Fenakel, A. Schattnera.
Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection.
Mayo Clin Proc, 75 (2000), pp. 355-359
[8.]
A. Lecube, C. Hernández, J. Genescà, J.I. Esteban, R. Jardi, R. Simó.
High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury.
Diabetes Care, 27 (2004), pp. 1171-1175
[9.]
S.J. Hadziyannis.
Nonhepatic manifestations and combined diseases in HCV infection.
Dig Dis Sci, 12 (1996), pp. 741-763
[10.]
M.C. Honeyman, N.L. Stone, L.C. Harrison.
T-cell epitopes in type 1 diabetes autoantigen tyrosine phosphatase IA2: potential mimicry with rotavirus and other envirommental agents.
Mol Med, 4 (1998), pp. 231-239
[11.]
S. Piquer, C. Hernández, J. Enriquez, A. Ross, I. Esteban, J. Genescà, et al.
Islet Cell and thyroid antibody prevalence in patients with hepatitis C virus infection: effect of treatment with interferon.
J Lab Clin Med, 137 (2001), pp. 38-42
[12.]
D.R. Nelson, H.L. Lim, C.G. Marousis, J.W. Fang, G.L. Davis, L. Shen, et al.
Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection.
Dig Dis Sci, 42 (1997), pp. 2487-2494
[13.]
K. Grungreiff, D. Reinhold, S. Ansorge.
Serum concentrations of sIL-2R, IL-6, TGF-beta1, neopterin, and zinc in chronic hepatitis C patients treated with interferon-alpha.
Cytokine, 11 (1999), pp. 1076-1080
[14.]
G.N. Ioannou, B.Y. Tung, K.V. Kowdley.
Iron in hepatitis C; villain or innocent bystander?.
Semin Gastrointest Dis, 13 (2002), pp. 95-108
[15.]
J.M. Fernández-Real, W. Ricart-Engel, E. Arroyo, R. Balanca, R. Casamitjana-Abella, D. Cabrero, et al.
Serum ferritin as a component of the insulin resistance syndrome.
Diabetes Care, 21 (1998), pp. 62-68
[16.]
J.T. Salonen, T.P. Tuomainen, K. Nyyssonen, H.M. Lakka, K. Punnonen.
Relation between iron stores and non-insulin dependent diabetes in men: case-control study.
BMJ, 317 (1998), pp. 727
[17.]
C. Hernández, J. Genescà, J.I. Esteban, R. García L Simó.
Relación entre los depósitos de hierro y la diabetes mellitus en pacientes infectados por el virus de la hepatitis C: estudio de casos y controles.
Med Clin (Barc), 115 (2000), pp. 21-22
[18.]
J.M. Fernandez-Real, A. López-Bermejo, W. Ricart.
Cross-talk between iron metabolism and diabetes.
Diabetes, 51 (2002), pp. 2348-2354
[19.]
A. Lecube, C. Hernández, L. García, J. Genescà, J. Esteban, J. Mesa, et al.
Diabetes is the main factor related to the high ferritin levels detected in patients with hepatitis C virus infection.
Diabetes, 52 (2003), pp. A541
[20.]
T. Frayling, S. Ellard, J. Grove, M. Walker, A.T. Hattersley.
C282Y mutation in HFE (haemochromatosis) gene and type 2 diabetes.
Lancet, 351 (1998), pp. 1993-1994
[21.]
J. Braun, H. Donner, K. Plock, H. Rau, K.H. Usadel, K. Badenhoop.
Hereditary haemochromatosis mutations (HFE) in patients with type II diabetes mellitus.
Diabetologia, 41 (1998), pp. 983-984
[22.]
S.F. Dinneen, J.D. Silverberg, K.P. Batts, P.C. O'Brien, D.J. Ballard, R.A. Rizza.
Liver iron stores in patients with non-insulin-dependent diabetes mellitus.
Mayo Clin Proc, 69 (1994), pp. 13-15
[23.]
S.A. Harrison, S. Kadakia, K.A. Lang, S. Schenker.
Non alcoholic stetaohepatitis: what we known in the new millenium.
Am J Gastroenterol, 97 (2002), pp. 2714-2724
[24.]
P. Angulo.
Non alcholic fatty liver disease.
N Engl J Med, 346 (2002), pp. 1221-1231
[25.]
C. Day, O. James.
Steatohepatitis: a tale of two “hits™?.
Gastroenterology, 114 (1998), pp. 842-845
[26.]
P. Angulo, K.D. Lindor.
Treatment of non-alcoholic steatohepatitis.
Best Pract Res Clin Gastroenterol, 16 (2002), pp. 797-810
Copyright © 2004. Sociedad Española de Endocrinología y Nutrición
